AU2002257004A1 - Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators - Google Patents

Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators

Info

Publication number
AU2002257004A1
AU2002257004A1 AU2002257004A AU2002257004A AU2002257004A1 AU 2002257004 A1 AU2002257004 A1 AU 2002257004A1 AU 2002257004 A AU2002257004 A AU 2002257004A AU 2002257004 A AU2002257004 A AU 2002257004A AU 2002257004 A1 AU2002257004 A1 AU 2002257004A1
Authority
AU
Australia
Prior art keywords
methods
angiogenesis
diagnosis
screening
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002257004A
Other languages
English (en)
Inventor
Natasha Aziz
Richard Glynne
Richard Murray
Susan R. Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of AU2002257004A1 publication Critical patent/AU2002257004A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002257004A 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators Abandoned AU2002257004A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US78435601A 2001-02-14 2001-02-14
US09/784,356 2001-02-14
US79139001A 2001-02-22 2001-02-22
US09/791,390 2001-02-22
US28547501P 2001-04-19 2001-04-19
US60/285,475 2001-04-19
US31002501P 2001-08-03 2001-08-03
US60/310,025 2001-08-03
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33424401P 2001-11-29 2001-11-29
US60/334,244 2001-11-29
PCT/US2002/004915 WO2002079492A2 (en) 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators

Publications (1)

Publication Number Publication Date
AU2002257004A1 true AU2002257004A1 (en) 2002-10-15

Family

ID=27559580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002257004A Abandoned AU2002257004A1 (en) 2001-02-14 2002-02-14 Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators

Country Status (5)

Country Link
EP (1) EP1418943A1 (ja)
JP (1) JP2004531249A (ja)
AU (1) AU2002257004A1 (ja)
CA (1) CA2438030A1 (ja)
WO (1) WO2002079492A2 (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP1385861A2 (en) 2000-10-25 2004-02-04 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
WO2003091447A2 (en) 2002-04-26 2003-11-06 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
US7622443B2 (en) 2002-04-26 2009-11-24 California Institute Of Technology Method for inhibiting pro-angiogenic activities of endothelial cells selectively at a site of neoangiogenesis in a mammal by administration of the extracellular domain of D1-1 polypeptides
JP2005537810A (ja) * 2002-09-11 2005-12-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
JP2007525167A (ja) 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
ATE494550T1 (de) 2003-04-25 2011-01-15 Takeda Pharmaceutical Neues screening-verfahren
US7267950B2 (en) * 2003-05-01 2007-09-11 Veridex, Lcc Rapid extraction of RNA from cells and tissues
US7833733B2 (en) 2003-06-09 2010-11-16 The University Of British Columbia Methods for detecting and treating cancer
US9309323B2 (en) 2003-06-09 2016-04-12 The University Of British Columbia Methods for detecting and treating cancer
JP2007527704A (ja) * 2003-06-30 2007-10-04 ジェノバ・リミテッド 心臓血管障害に関連する分泌ポリペプチド種
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
DE10340373A1 (de) * 2003-08-30 2005-03-24 Henkel Kgaa Verfahren zur Bestimmung von Haarzyklus-Marken
JP2005073621A (ja) * 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
WO2005069855A2 (en) 2004-01-13 2005-08-04 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
BRPI0509177A (pt) 2004-03-24 2007-09-18 Pdl Biopharma Inc uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas
EP1743944A4 (en) 2004-04-23 2011-01-05 Takeda Pharmaceutical NEW SCREENING PROCEDURE
WO2005113788A2 (en) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
JP4994379B2 (ja) * 2005-09-01 2012-08-08 ブリストル−マイヤーズ スクイブ カンパニー 血管内皮成長因子受容体−２モジュレーターに対する感受性を決定するためのバイオマーカーおよび方法
WO2007095353A2 (en) * 2006-02-14 2007-08-23 Geisinger Clinic Gpcrs as angiogenesis targets
US20090028793A1 (en) * 2006-02-22 2009-01-29 Philogen Spa Vascular Tumor Markers
MX2008011905A (es) 2006-03-21 2008-09-30 Genentech Inc Terapia de combinacion.
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2016394A4 (en) 2006-04-04 2013-04-24 Singulex Inc METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES
JP5312459B2 (ja) 2007-08-02 2013-10-09 ジリード バイオロジクス，インク． Ｌｏｘおよびｌｏｘｌ２阻害剤ならびにこれらの使用
SI2200700T1 (sl) 2007-09-26 2016-04-29 Genentech, Inc. Nova protitelesa
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
EP2216399A1 (en) 2009-01-30 2010-08-11 Université de la Méditerranée Human soluble CD146, preparation and uses thereof
RU2011142974A (ru) 2009-03-25 2013-04-27 Дженентек, Инк. НОВЫЕ АНТИТЕЛА ПРОТИВ α5β1 И ИХ ПРИМЕНЕНИЕ
EP2440936A4 (en) 2009-06-08 2013-03-13 Singulex Inc GROUPS OF HIGHLY SENSITIVE BIOMARKERS
WO2011004837A1 (ja) 2009-07-08 2011-01-13 株式会社ＡＣＴＧｅｎ 抗癌活性を有する抗体
AU2010284036B2 (en) 2009-08-21 2014-12-18 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors

Also Published As

Publication number Publication date
WO2002079492A8 (en) 2004-03-25
EP1418943A1 (en) 2004-05-19
CA2438030A1 (en) 2002-10-10
WO2002079492A2 (en) 2002-10-10
JP2004531249A (ja) 2004-10-14

Similar Documents

Publication Publication Date Title
WO2002079492A8 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002330039A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU6902200A (en) Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2002068677A8 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
WO2003022987A9 (en) Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
AU2001290902A1 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2002306918A1 (en) Methods of modulating angiogenesis
AU2002242996A1 (en) Spiroisoquinoline compounds, methods for their preparation and intermediates
AU2002249467A1 (en) Screening method
AU2002357734A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2002367145A1 (en) Remedies for anorexia or lifestyle-related diseases and method of screening the same
AU2002332696A1 (en) Solid support dirhodium catalyst compositions and methods for making and using same
AU2002307413A1 (en) Modulators of angiogenesis
AU2002331753A1 (en) Dirhodium catalyst compositions and methods for using same
AU2002353772A1 (en) Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
AU2002348191A1 (en) Method and composition for the modulation of angiogenesis
AU2002354206A1 (en) Method of screening drug
AU2002347578A1 (en) Process for the preparation of dronedarone

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase